science group plc

2024 Interim Results

Martyn Ratcliffe

Executive Chair

Dan Edwards

Group Managing Director

Jon Brett

Group Finance Director

To be read in conjunction with the Interim Results announcement released on 23 July 2024

Financial Summary

Group Revenue

£53.7m

H1-23: £56.1m

Adjusted Operating Profit

£11.0m

H1-23: £10.4m

Group Cash (excl. client funds)

£38.8m

H1-23: £29.2m

Net Funds

£26.4m

H1-23: £15.7m

Earnings Per Share (adj. basic)

18.1p

H1 in line with Board expectations

Record Adjusted Operating Profit ('AOP')

AOP margin of 20.5%

Resilient performance in uncertain environment

Consultancy Services

Premium AOP margin

Respectable performance against challenging prior year comparator and general consultancy market conditions

Increasing integration of operations

Systems Businesses

Significant increase in Revenue and AOP

CMS2 turnaround delivering significant contribution

Frontier recovery making progress

Strong Balance Sheet


Group Cash of £38.8m (H1-23: £29.2m)

Net Funds of £26.4m (H1-23: £15.7m)

Increased 2024 share buyback up to £5.0m


Group Performance Summary

- Record half-year Adjusted Operating Profit of £11.0m (H1-23: £10.4m)
- Revenue of £53.7m (H1-23: £56.1m)
- Group AOP Margin of 20.5% (H1-23: 18.6%)
- Consultancy Services reporting against challenging prior year comparator
- Strong performance from CMS2



Group Balance Sheet and Cash Flow

- Strong cash balance
 - Group cash of £38.8m (H1-23: £29.2m)
 - Net funds of £26.4m (H1-23: £15.7m)
- Good working capital management and operating business cash conversion
 - Cash generated from operations of £10.7m (H1-23: £7.2m), prior to dividend payment in July
 - Inventory days (Frontier primarily) normalise to pre-Covid levels
- Two freehold properties in Cambridge and Epsom




Consultancy Services Division - Financial

Financial Summary

- Revenue of £36.5m (H1-23: £42.3m)
 - Softer consultancy market from mid-2023
 - Challenging prior year comparator (H1-23)
- AOP of £8.8m in line with H2-23
 - (H1-23: £11.5m; H2-23: £8.9m)

Sector Commentary

- Medical: large projects completed in H1-23 but sequential revenue growth relative to H2-23
- Industrial: large projects completed in 2023 and sector remains subdued
- Defence & Aerospace: management action to reduce low-margin legacy activities coincided with slow-down in run-up to UK election
- Consumer: satisfactory performance



Consultancy Services Division - Operations

Practice and Sector Capabilities

| | Science & Technology | Regulatory /Safety | Programme Mgmt | Product Dev |
|-----------------------------------|-------------------------|-----------------------|-------------------|----------------|
| Industrial/ Chemicals | ✓ | ✓ | | ✓ |
| Medical | ✓ | | | ✓ |
| Defence & Aerospace | ✓ | (Aerospace) | ✓ | ✓ |
| Consumer (incl. Food & Bev) | ✓ | ✓ | | √ |

Increasing Consultancy Integration

- Continual focus on operational effectiveness and efficiency drives strong margins
- Coordinated account management to maximise synergies in common clients
- Integrating Practice marketing teams into single Consultancy organisation
- Single IT ERP platform across all Consultancy operations being implemented
 - Regulatory businesses completed
 - Defence & Aerospace being migrated in H2 2024
 - R&D transition in process
- Consolidating finance function including shared service model for transaction processing

CMS2 - Financial

Successful turnaround

- Excellent financial performance
- Revenue increased to £10.9m (5 months H1-23: £7.9m)
- Significant increase in AOP to £3.2m (5 months H1-23: £0.8m)
- Revenue timing variability due to project scale


Benefitting from commercial discipline and operational focus

- Exiting non-core and low-margin activities
- Renegotiating onerous contracts
- Significantly reduced contract risk profile
- Operational improvement programme
- Restructuring of in-service support model


Well-positioned for the future in attractive market sector

- Decades of experience and expertise
- Good visibility of UK and international boat programmes

Revenue by Geography



Revenue by Type



CMS2 – Market Opportunity

Leading market position (outside USA)

- Limited competition for systems capable of supporting extended underwater deployment
- Installed base gives unparallelled experience and capability
- Incumbent supplier to the UK Navy for all major classes of submarine
- Addressable market growing as strategic importance of submarines is increasingly recognised
- Investment in next-generation systems (12 patents filed in the period)

Good revenue visibility over submarine system lifecycle

- Systems currently being manufactured and commissioned for UK and international navies
- Design/Build revenues 1-4 years from initial contract
- Install/Commission revenues 1-3 years from system supply
- In-Service Support revenues over 25+ year operational life of boat

Growing in-service support programme

- Commercial discipline to ensure all activities are profitable
- Active migration from ad hoc support to term contracts
- First international customer contracted to support programme
- 2 year extension of UK support contract, renegotiated and signed in June 2024

Frontier

Revenue of £5.9m (H1-23: £5.4m; H2-23: £4.5m)

- Business returns to break even
- Channel inventory levels normalising


Connected Audio

- Continued investment in R&D
- All costs expensed, not capitalised
- New product, Auria, well advanced
- Opens up potential new product categories


Business Evolution

- UK focused on semiconductor and module design, development and supply
- Asia operations provide sales and customer support incl. customisation services for clients
- Internet content service being outsourced
 - Consistent model with streaming music services, podcasts and other services
 - Reduced fixed infrastructure costs
 - Simplification of business model

Volumes by Product



Market Dynamics



science group plc

Disclaimer Statement

This document contains forward-looking statements. These have been made by the Board in good faith based on the information available to them and it is believed that the expectations reflected in these statements are reasonable. However, due to the inherent uncertainties, including both economic and other risk factors underlying such forward-looking information, the Directors can give no assurance that these expectations will prove to be correct. Actual results may differ materially from those expressed or implied, and investors should not place undue reliance on any such forward-looking statements. Nothing in this document should be construed as a profit forecast, or a guide as to the performance, financial or otherwise of the Company whether in the current or any future financial year.

No representation or warranty is made as to the achievement or reasonableness of, and no reliance should be placed on such forward-looking statements. The forward-looking statements contained in this document speak only as of the date of this document. The Company undertakes no obligation to update or revise any information contained in this document, except as may be required by applicable law or regulation.

The Board, officers, members, employees, agents or advisers of the Company expressly disclaim any liability for any direct, indirect or consequential loss or damage (including, without limitation, loss of profit) suffered by any person as a result of any obligation or undertaking to disseminate any updates, revisions or corrections to any forward looking statements or other information contained in the document, including to reflect any change in the Company's expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.